Skip to main content

Advertisement

Log in

Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

Cluster of differentiation 38 (CD38) is a promising therapeutic target in multiple myeloma (MM) patients and has resulted in the development of several CD38 immunotherapies. Current methods to evaluate CD38 expression in the preclinical setting include ex vivo flow cytometry and immunohistochemistry, which can be cumbersome and do not give whole-body information. In vivo imaging technologies such as positron emission tomography rely on decay of radioisotopes, limiting the number of molecular interactions observed at any given time point. Here, we demonstrate the use of near-infrared (NIR) fluorescence imaging for spatiotemporal monitoring of CD38 expression in preclinical MM using the anti-CD38 daratumumab (DARA) conjugated to the NIR fluorophore IRDye800CW (DARA-IRDye800).

Procedures

Stability studies with human serum and binding assays with human myeloma cells were performed with DARA-IRDye800. Immunocompromised mice with intra- and extramedullary tumors (n = 5/group) were administered with DARA-IRDye800 for in vivo imaging up to 7 days after injection. Ex vivo biodistribution and flow cytometry studies were performed to validate in vivo imaging results. A separate therapy study was performed in mice with intramedullary tumors that were treated and not treated with DARA at a therapeutic dose (n = 7/group). DARA-IRDye800 was administered for subsequent in vivo and ex vivo imaging in both cohorts of mice.

Results

DARA-IRDye800 maintained stability and had high affinity for CD38 (KD = 3.5 ± 0.05 nM). DARA-IRDye800 demonstrated a 5- and 18-fold increase in contrast in tumor-bearing regions of mice with extra- and intramedullary MM. Finally, mice treated with therapeutic doses of DARA and imaged with DARA-IRDye800 showed an 11-fold decrease in fluorescence intensities in vivo compared with untreated controls.

Conclusions

Our studies establish DARA-IRDye800 as a promising contrast agent for preclinical evaluation of CD38 expression and for further investigating myeloma engraftment and kinetics in relation to anti-CD38 therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2
Fig. 3
Fig. 4.
Fig. 5.
Fig. 6.

Similar content being viewed by others

References

  1. Hogan KA, Chini CCS, Chini EN (2019) The multi-faceted Ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol 10:1–12

    Article  Google Scholar 

  2. Ghose J, Viola D, Terrazas C et al (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:1–11

    Article  Google Scholar 

  3. Malavasi F, Deaglio S, Damle R et al (2011) CD38 and chronic lymphocytic leukemia: a decade later. Blood 118:3470–3478

    Article  CAS  Google Scholar 

  4. Martin TG, Corzo K, Chiron M et al (2019) Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells 8:1522

    Article  CAS  Google Scholar 

  5. van de Donk NWCJ, Janmaat ML, Mutis T et al (2016) Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 270:95–112

    Article  Google Scholar 

  6. Moreno L, Perez C, Zabaleta A et al (2019) The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res 25:3176–3187

    Article  CAS  Google Scholar 

  7. Syed K, Nijhof IS, van Velzen J et al (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128:959–970

    PubMed  Google Scholar 

  8. Nijhof IS, Groen RWJ, Lokhorst HM et al (2015) Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29:2039–2049

    Article  CAS  Google Scholar 

  9. Warram JM, de Boer E, Sorace AG et al (2014) Antibody-based imaging strategies for cancer. Cancer Metastasis Rev 33:809–822

    Article  CAS  Google Scholar 

  10. Ghai A, Maji D, Cho N et al (2018) Preclinical development of CD38-targeted [89 Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med 59:216–222

    Article  CAS  Google Scholar 

  11. Moses WW (2011) Fundamental limits of spatial resolution in PET. Nucl Instrum Methods Phys Res Sect A Accel Spectrom Detect Assoc Equip 648:S236–S240

    Article  CAS  Google Scholar 

  12. Smith AM, Mancini MC, Nie S (2009) Bioimaging: second window for in vivo imaging. Nat Nanotechnol 4:710–711

    Article  CAS  Google Scholar 

  13. Lokhorst HM, Plesner T, Laubach JP et al (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207–1219

    Article  CAS  Google Scholar 

  14. Oliveira S, Cohen R, van Walsum MS et al (2012) A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Res 2:1–9

    Article  Google Scholar 

  15. Zhang K (2008) Center for Drug Evaluation and Pharmacology Review ( S ): Olopatadine NDA21861. Pharmacol NDA Rev Eval 1–214

  16. Oyajobi BO, Muñoz S, Kakonen R et al (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 6:1701–1708

    Article  CAS  Google Scholar 

  17. Cho N, Shokeen M (2019) Changing landscape of optical imaging in skeletal metastases. J Bone Oncol 17:100249

    Article  Google Scholar 

  18. Ma T, Sun X, Cui L et al (2014) Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med 55:1002–1007

    Article  CAS  Google Scholar 

  19. Liu Z, Sun X, Liu H et al (2014) Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med 55:818–823

    Article  CAS  Google Scholar 

  20. Fairfield H, Falank C, Avery L, Reagan MR (2016) Multiple myeloma in the marrow: Pathogenesis and treatments. Ann N Y Acad Sci 1364:32–51

    Article  CAS  Google Scholar 

  21. Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6:576–588

    Article  CAS  Google Scholar 

  22. Eigenmann MJ, Fronton L, Grimm HP et al (2017) Quantification of IgG monoclonal antibody clearance in tissues. MAbs 9:1007–1015

    Article  CAS  Google Scholar 

  23. Paton-Hough J, Chantry AD, Lawson MA (2015) A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone 77:57–68

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. Samuel Achilefu for providing expert advice throughout all phases of the project. We are grateful to Dr. Christine O’Brien for her assistance with image analysis. We also acknowledge Matthew Mixdorf for his assistance with flow cytometry studies. Special thanks to Gail Sudlow, Amanda Klaas, Margaret Morris, and Julie Prior for assistance with animal model and intravenous injections.

Funding

This work has been supported by National Cancer Institute (NCI) R01 CA248493, NCI funded Center for Multiple Myeloma Nanotherapy (U54 CA199092), the Imaging Sciences Pathway fellowship (T32 EB014855), Molecular Imaging Center (NIH P50 CA094056), Siteman Cancer Center Small Animal Cancer Imaging shared resource (NCI P30 CA091842), and the Nutrition Obesity Research Center (P30 DK056341).

Author information

Authors and Affiliations

Authors

Contributions

Nicholas Cho contributed to the design and execution of all studies and data analysis and prepared the draft of the manuscript. Sooah Ko independently executed serum stability assay and provided additional support in conducting other studies. Dr. Monica Shokeen led the study, helped design experiments, and reviewed and revised the subsequent versions of the manuscript.

Corresponding author

Correspondence to Monica Shokeen.

Ethics declarations

Conflict of Interest

Mr. Cho, Ms. Ko, and Dr. Shokeen all report grants from National Cancer Institute, grants from National Cancer Institute Center of Multiple Myeloma Nanotherapy, grants from Washington University Imaging Sciences Pathway Fellowship, grants from Washington University Molecular Imaging Core, grants from Siteman Cancer Center Small Animal Cancer Imaging shared resource, and grants from Washington University Nutrition Obesity Research Center during the conduct of the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(JPG 612 kb)

ESM 2

(JPG 534 kb)

ESM 3

(JPG 619 kb)

ESM 4

(JPG 1697 kb)

ESM 5

(JPG 133 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, N., Ko, S. & Shokeen, M. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma. Mol Imaging Biol 23, 186–195 (2021). https://doi.org/10.1007/s11307-020-01542-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-020-01542-4

Key words

Navigation